January 15, 2019 Acad, Gov/Utilities M&A, Partnerships Materials Analysis

MTS Equips University To Test New Materials For Construction And Transportation Industries

EDEN PRAIRIE, Minn., Jan. 15, 2019 /PRNewswire/ — MTS Systems Corporation (NASDAQ: MTSC), a leading global supplier of high-performance test systems, motion simulators and sensors, today announced completion of two unique test systems for the Extreme Performance Testing Center at Seoul National University. These test systems—a High-Rate Impact and a High-Force Fatigue system—deliver the velocities... Read more

January 14, 2019 Acad, Gov/Utilities Clinical Research/Diagn. Product Launch

QIAGEN’s QuantiFERON®-TB Gold Plus gains approval in Canada

Germantown, Maryland and Hilden, Germany, January 14th, 2019 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the Health Canada regulatory approval of QuantiFERON®-TB Gold Plus (QFT®-Plus) as an in vitro diagnostic test to detect latent tuberculosis (TB) infection. QFT-Plus is the fourth generation of QIAGEN’s market-leading QuantiFERON-TB technology, combining a new flexible... Read more

January 4, 2019 Acad, Gov/Utilities M&A, Partnerships

GE Healthcare, Vanderbilt University Medical Center partner for safer, more precise immunotherapy cancer treatment

Chicago and Nashville, USA – January 6, 2019 – GE Healthcare and Vanderbilt University Medical Center (VUMC) today announced a five-year partnership to enable safer and more precise cancer immunotherapies. Multiple diagnostic tools will be developed to help predict both the efficacy of an immunotherapy treatment and its adverse effects for a specific patient before... Read more

December 17, 2018 Acad, Gov/Utilities Licensing, IP, and Legal

PRIME designation granted by European Medicines Agency for Roche’s risdiplam for treatment of spinal muscular atrophy (SMA)

Basel, 17 December 2018 PRIME designation granted by European Medicines Agency for Roche’s risdiplam for treatment of spinal muscular atrophy (SMA) Risdiplam has the potential to be the first oral medicine for the treatment of SMA Types 1, 2 and 3; a rare and debilitating genetic disease most commonly diagnosed in children European Medicines Agency PRIME... Read more

December 10, 2018 Acad, Gov/Utilities Bio/Pharma/CRO Lab Top-10 Life Science Tools M&A, Partnerships

Merck KGaA, Darmstadt, Germany Announces a CRISPR/Cas9 Strategic Alliance to Develop Rodent Models with genOway

10 DEC 2018 | DARMSTADT, GERMANY genOway to acquire exclusive rights to Merck’s foundational genome-editing patents to produce, sell rodent models New technologies and solutions to be developed using CRISPR/Cas9 to accelerate delivery of better drugs to patients Merck KGaA, Darmstadt, Germany, a leading science and technology company and leader in genome editing, announced that its life... Read more

December 7, 2018 Acad, Gov/Utilities

FDA approves Roche’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer

Basel, 07 December 2018 FDA approves Roche’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer Approval based on survival benefit of Tecentriq in combination with Avastin, paclitaxel and carboplatin (chemotherapy) in people with metastatic non-squamous non-small cell lung cancer (NSCLC) with no... Read more

December 5, 2018 Acad, Gov/Utilities

FDA grants priority review to Roche’s Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer

Basel, 05 December 2018 FDA grants priority review to Roche’s Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) and granted Priority Review for... Read more

November 21, 2018 Acad, Gov/Utilities Product Launch

Roche announces FDA grants Venclexta accelerated approval for people with newly-diagnosed acute myeloid leukaemia or those who are ineligible for intensive induction chemotherapy

Basel, 21 November 2018 Roche announces FDA grants Venclexta accelerated approval for people with newly-diagnosed acute myeloid leukaemia or those who are ineligible for intensive induction chemotherapy Approval based on two studies that showed durable remissions in people with newly-diagnosed acute myeloid leukaemia, who are age 75 years or older, or for those ineligible for... Read more

November 19, 2018 Acad, Gov/Utilities Environ, Ag./Food & Bev PR/Corporate

Scientist behind plant fingerprint receives the Nils Foss Excellence Prize of €100,000

  HILLERØD, November 19, 2018 – Today, FOSS awarded Professor Robert David Hall the Nils Foss Excellence Prize for his pioneering research in plant metabolomics – the chemical fingerprint of plant cells. The award consists of 100,000 euro and this year in particular, it carries special meaning. FOSS, the world’s leading supplier of analytical solutions... Read more

November 19, 2018 Acad, Gov/Utilities

Xylem signs Memorandum of Understanding with the Government of Ethiopia to explore helping country solve water challenges

RYE BROOK, N.Y.–(BUSINESS WIRE)–Nov. 19, 2018– Xylem Inc. (NYSE: XYL), a leading global water technology provider, has signed a Memorandum of Understanding (MoU) with Ethiopia’s Ministry of Water, Irrigation and Energy (MoWIE) for future cooperation to help advance water security in Ethiopia. The MoU was signed at an event in Ethiopia attended by Ethiopia’s Minister of Water, Irrigation and... Read more